Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Young Adults
NCT02166463Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2015
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by National Cancer Institute. Started Mar 2015; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02166463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02166463.